GSC2 inhibitors are a category of chemical agents that specifically target and inhibit the activity of an enzyme known as glucosylceramide synthase 2 (GSC2). This enzyme is involved in the biosynthesis of glycosphingolipids, which are essential components of cell membranes and play a crucial role in various cellular processes, including cell-to-cell communication, cell differentiation, and the modulation of cell signaling pathways. GSC2 inhibitors work by binding to the active site of the enzyme or by interacting with its allosteric sites, thereby altering its conformation and function. This inhibition disrupts the normal synthesis of glycosphingolipids, which can have profound effects on the physiological state of a cell, particularly concerning the composition and properties of its membrane.
The design and development of GSC2 inhibitors involve a deep understanding of the enzyme's structure and the molecular mechanisms that govern its function. Researchers use various techniques, such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling, to elucidate the three-dimensional structure of the enzyme in complex with potential inhibitors. This structural information is vital for identifying key interactions between the enzyme and the inhibitor and for designing molecules that can effectively block the enzyme's activity. GSC2 inhibitors are typically small organic molecules, although peptide-based inhibitors can also be designed.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
This is a BMP type I receptors inhibitor, such as ALK2, ALK3, and ALK6, which disrupts the BMP signaling. By hampering BMP pathway activation, GSC2 can be indirectly influenced. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
Specifically inhibits BMP type I receptors ALK2 and ALK3, which are crucial for BMP pathway activation. This can lead to reduced GSC2 activity indirectly. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
An ALK2 inhibitor, it disrupts BMP pathway signaling, which can result in GSC2 modulation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
This compound inhibits ALK5, ALK4, and ALK7, which are not directly associated with BMP but can have cross-talk effects that can lead to GSC2 modulation. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
Inhibits ALK2 specifically, preventing BMP pathway signaling, which can modulate GSC2 activity. | ||||||
K02288 | 1431985-92-0 | sc-488981 | 5 mg | $330.00 | ||
Another ALK2 inhibitor, it halts BMP signaling, and this disruption can lead to altered GSC2 function. | ||||||